drugset / Trial / NCT00927836

AXIS 2: AX200 for the Treatment of Ischemic Stroke

NCT00927836

Phase 2 Completed 328 enrolled Sygnis Bioscience GmbH & Co KG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.

Timeline

Start
2009-05
Primary completion
2011-11
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic 135 ug/kg Intravenous

Indications